{"product_id":"auroramj-swot-analysis","title":"Aurora SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAurora’s SWOT highlights solid R\u0026amp;D capabilities and strategic partnerships, counterbalanced by capital intensity and regulatory exposure; our full analysis dissects market positioning, competitive threats, and growth levers to guide decisions. Purchase the complete SWOT to receive a professionally formatted, editable report and Excel matrix—designed for investors, strategists, and advisors who need actionable, research-backed insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Global Medical Cannabis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora has become a dominant force in international medical cannabis, capturing an estimated 18% share of Germany’s prescription market and holding leading positions in Poland and Australia by end-2025. Medical sales now represent about 62% of group revenue, with gross margins near 48% versus ~30% for recreational products. Its emphasis on medical-grade quality and regulatory compliance has produced recurring contracts with hospitals and pharmacies, stabilizing cash flow against consumer volatility. Recent EU and TGA approvals support predictable 2026 export growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genetics and Intellectual Property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora uses its Occasio facility for advanced breeding and genetics, producing higher-yielding, more resilient cannabis strains that raised indoor yields by ~12% in 2024 versus company averages. Proprietary genetics deliver targeted cannabinoid profiles—driving premium product premiums and commanding higher patient retention. Aurora licenses these genetics to other producers, creating a high-margin revenue stream that contributed an estimated CAD 8–12 million in 2024 licensing revenue. This leverages scientific IP to scale margins without expanding cultivation footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Diversification via Bevo Agro\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpthe acquisition of bevo agro gave aurora a foothold in plant propagation and vegetable greenhouses adding segment that generated roughly cad million annual revenue for providing steady cash flow versus cannabis volatility.\u003e\n\u003cpbevo operations smooth seasonal swings: greenhouse produce sells year-round and reduced aurora quarterly revenue variance by an estimated in\u003e\n\u003cpbevo tech improved aurora nursery yields by and cut seedling losses from to at key cultivation sites boosting overall efficiency.\u003e\n\u003c\/pbevo\u003e\u003c\/pbevo\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrengthened Balance Sheet and Cash Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough rigorous cost cuts and debt restructuring completed by late aurora reduced net to about cad million reported cash on hand at fy2025 giving it one of the strongest balance sheets among canadian licensed producers.\u003e\n\u003cpthe company eliminated million of convertible debt cutting annual interest and dilution risk freeing in yearly cash flow for reinvestment.\u003e\n\u003cpthis fiscal strength lets aurora fund growth projects and m without immediate dilutive equity raises preserving shareholder value.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt ~CAD 120M\u003c\/li\u003e\n\u003cli\u003eCash on hand ~CAD 220M\u003c\/li\u003e\n\u003cli\u003eConvertible debt eliminated ~CAD 200M\u003c\/li\u003e\n\u003cli\u003eAnnual interest savings ~CAD 25M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliance and Regulatory Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora runs a sophisticated regulatory framework enabling exports to 25+ countries across North America, Europe and APAC, keeping 98% of shipments EU GMP-compliant as of FY2024.\u003c\/p\u003e\n\u003cp\u003eThis expertise creates a high barrier to entry for smaller rivals lacking GMP infrastructure and helped secure €45m in government supply contracts through 2025.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e98% EU GMP-compliant shipments (FY2024)\u003c\/li\u003e\n\u003cli\u003eExports to 25+ countries\u003c\/li\u003e\n\u003cli\u003e€45m in government contracts through 2025\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: Dominant German med‑cannabis leader—18% market share, €45M contracts, strong margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora leads in medical cannabis with ~18% of Germany’s prescription market, 62% of group revenue from medical sales, ~48% medical gross margin, CAD 120M net debt, CAD 220M cash (FY2025), CAD 45–50M Bevo revenue (2024), exports to 25+ countries and €45M government contracts through 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany market share\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical revenue\u003c\/td\u003e\n\u003ctd\u003e62% of group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical gross margin\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY2025)\u003c\/td\u003e\n\u003ctd\u003eCAD 120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on hand (FY2025)\u003c\/td\u003e\n\u003ctd\u003eCAD 220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eCAD 45–50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport markets\u003c\/td\u003e\n\u003ctd\u003e25+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt contracts\u003c\/td\u003e\n\u003ctd\u003e€45M through 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Aurora’s competitive position by outlining its internal strengths and weaknesses alongside external opportunities and threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a clear Aurora SWOT snapshot for rapid strategic alignment and concise stakeholder briefs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Significant Share Dilution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora Cannabis saw its diluted share count jump from about 1.0 billion in 2018 to roughly 4.0 billion by 2023 after repeated equity raises, eroding EPS power for long-term holders.\u003c\/p\u003e\n\u003cp\u003eManagement has cut cash burn and slowed raises since 2022, but the legacy dilution still depresses per-share metrics and hurt sentiment, limiting upside as buybacks remain unconfirmed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in the Canadian Retail Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite international medical success, Aurora Cannabis remains concentrated in the Canadian adult‑use market where retail oversaturation (over 3,300 stores nationwide by 2024) and promotion-heavy discount brands have pushed gross margins down; Aurora reported Canadian cannabis segment gross margin near single digits in FY2024, dragging consolidated margins compared with double‑digit margins in its international medical operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Specific International Jurisdictions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora earns roughly 45% of 2024 revenue from Germany (27%) and Australia (18%), concentrating growth in just two markets; any abrupt political shifts or tighter import rules there could cut top-line by a third in a worst-case year. \u003c\/p\u003e\n\u003cp\u003eThis geographic concentration raises regulatory risk: a 2023 German tax change and Australia’s 2022 import licensing tightening show how quickly margins and cash flow can be squeezed. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Infrastructure Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpaurora still runs a sprawling asset base despite closing several underperforming facilities keeping annual maintenance and operational costs high reported capital expenditures of ca million in fy2024 impairment charges\u003e\n\u003cpthe shift from a large cultivation model to leaner specialized producer has been costly and slow with divestitures retooling stretching through lowering near-term margins.\u003e\n\u003cpthese legacy overheads sometimes slow product launches and limit quick entry into emerging markets reducing agility versus smaller rivals.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCA$90M capex (FY2024)\u003c\/li\u003e\n\u003cli\u003eCA$120M impairments (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year retooling 2023–2025\u003c\/li\u003e\n\u003cli\u003eReduced agility vs smaller peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pthe\u003e\u003c\/paurora\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegative GAAP Net Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite positive adjusted EBITDA of C$120 million in FY2024, Aurora Cannabis reported a GAAP net loss of C$85 million for the year due to C$70 million in depreciation, amortization, and C$60 million of impairment charges tied to past acquisitions.\u003c\/p\u003e\n\u003cp\u003eAnalysts remain cautious until Aurora shows sustained GAAP profitability and a repeatable cash-to-net-income conversion path; volatility in non-cash charges makes trends hard to trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 adjusted EBITDA: C$120M\u003c\/li\u003e\n\u003cli\u003eFY2024 GAAP net loss: C$85M\u003c\/li\u003e\n\u003cli\u003eDepreciation \u0026amp; amortization: C$70M\u003c\/li\u003e\n\u003cli\u003eImpairments: C$60M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: 4x Dilution, Margin Squeeze, Geo Concentration \u0026amp; C$85M Loss in FY2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora’s legacy dilution (1.0B→4.0B shares, 2018–2023) and unconfirmed buybacks depress EPS; Canadian retail oversupply drove FY2024 Canadian gross margin near single digits versus double digits internationally; revenue concentration (Germany 27%, Australia 18% of 2024) heightens regulatory risk; FY2024: adjusted EBITDA C$120M, GAAP net loss C$85M, capex C$90M, impairments C$120M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares diluted (2018→2023)\u003c\/td\u003e\n\u003ctd\u003e1.0B → 4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralia revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eC$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 GAAP net loss\u003c\/td\u003e\n\u003ctd\u003eC$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 capex\u003c\/td\u003e\n\u003ctd\u003eCA$90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 impairments\u003c\/td\u003e\n\u003ctd\u003eCA$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAurora SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, and the complete, editable version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752336241017,"sku":"auroramj-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/auroramj-swot-analysis.png?v=1772239679","url":"https:\/\/growthsharematrix.com\/products\/auroramj-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}